Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jun 09, 2024 10:43am
68 Views
Post# 36079860

Osteoarthritis and avenanthramide

Osteoarthritis and avenanthramide
  1. The high prevalence of osteoarthritis, especially in the aging population, is a major driver for the demand for NSAIDs as they are commonly prescribed for managing osteoarthritis pain and inflammation .   
Based on the search results provided, avenanthramides, particularly avenanthramide C (Avn-C), show promising potential for treating osteoarthritis (OA), which is a type of arthritis.Here are the key points:
  1. The study by Tran et al.  demonstrated that Avn-C effectively prevented cartilage destruction and alleviated osteoarthritic pathogenesis in an experimental OA mouse model. Avn-C inhibited the expression and activity of matrix metalloproteinases (MMPs) like MMP-3, MMP-12, and MMP-13, which are responsible for cartilage degradation in OA.
  2. The anti-inflammatory and cartilage-protective effects of Avn-C were mediated through the inhibition of p38 kinase and c-Jun N-terminal kinase (JNK) signaling pathways in chondrocytes (cartilage cells).
  3. While the study  focused on the efficacy of Avn-C in an OA model, it suggests that avenanthramides could be promising candidates for treating OA and preventing its progression.
  4. However, the study  was conducted in vitro and in an animal model. Clinical trials in humans are still needed to evaluate the efficacy and safety of avenanthramides for treating OA or other forms of arthritis.
  5. Ceapro Inc. is currently conducting a Phase I/IIa clinical trial  to assess the safety, tolerability, and bioavailability of a pharmaceutical-grade avenanthramide tablet in healthy individuals and those with low-grade inflammation. This trial could provide preliminary insights into the anti-inflammatory potential of avenanthramides in humans.
In summary, while the preclinical evidence  is encouraging, more clinical research is needed to determine if avenanthramides can effectively treat osteoarthritis or other types of arthritis in humans. The ongoing clinical trial  by Ceapro Inc. is an important step in evaluating the therapeutic potential of avenanthramides for inflammatory conditions like arthritis.
<< Previous
Bullboard Posts
Next >>